First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Valion Bio

    VALB · 2 developments mapped · last assessed 2026-08-31

    Market Ontology has mapped 2 macro, policy, and market developments to Valion Bio since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for VALB yet, so no modelled value is shown. The VALB valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run VALB on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for VALB. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Main threat

      Valion Bio Announces 1-for-25 Reverse Stock Split

      A reverse stock split, especially one driven by compliance issues, often signals underlying financial distress or lack of investor confidence. While it addresses a technical listing requirement, it does not fundamentally improve the company's business operations or financial health. It can lead to i

      · Moves perceived financial health and growth prospects, investor sentiment and liquidity, risk premium

    What changed, by assumption

    Perceived financial health and growth prospects
    • 2026-08-31Valion Bio Announces 1-for-25 Reverse Stock Split
    Market perception of risk
    • 2026-08-27Valion Bio Announces 1-for-25 Reverse Stock Split

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-31Valion Bio Announces 1-for-25 Reverse Stock SplitBearish1-3m0.70
    2026-08-27Valion Bio Announces 1-for-25 Reverse Stock SplitBearish1-3m0.70